Difference between revisions of "Dacarbazine (DTIC)"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
m (Text replacement - "analogues" to "analogs")
 
(32 intermediate revisions by 4 users not shown)
Line 1: Line 1:
 
==General information==
 
==General information==
−
Class/mechanism: Alkylator, purine analog, inhibits DNA synthesis; exact mechanism unclear. Converted to the active alkylating metabolite MTIC.<ref name="insert">[http://patient.cancerconsultants.com/druginserts/Dacarbazine.pdf Dacarbazine (DTIC) package insert]</ref><ref>[[Media:Dacarbazine.pdf | Dacarbazine (DTIC) package insert (locally hosted backup)]]</ref>
+
Class/mechanism: Alkylator, purine analog, inhibits DNA synthesis; exact mechanism unclear. Converted to the active alkylating metabolite MTIC.<ref name="insert">[https://labeling.pfizer.com/ShowLabeling.aspx?id=5938 Dacarbazine (DTIC) package insert]</ref><ref>[[:File:Dacarbazine.pdf | Dacarbazine (DTIC) package insert (locally hosted backup)]]</ref>
 
<br>Route: IV
 
<br>Route: IV
 
<br>Extravasation: [[irritant]]
 
<br>Extravasation: [[irritant]]
  
−
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.<ref name="insert"></ref>  
+
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.<ref name="insert"></ref>  
 +
==Diseases for which it is established ''(work in progress)''==
 +
*[[Classical Hodgkin lymphoma]]
 +
*[[Melanoma]]
 +
**[[Uveal melanoma]]
  
 
==Diseases for which it is used==
 
==Diseases for which it is used==
−
*[[Hodgkin lymphoma]]
 
 
*[[Hodgkin lymphoma, nodular lymphocyte-predominant]]
 
*[[Hodgkin lymphoma, nodular lymphocyte-predominant]]
−
*[[Melanoma]]
+
*[[Neuroblastoma]]
−
*[[Neuroendocrine tumors]]
+
*[[Pheochromocytoma]]
−
*[[Sarcoma]]
+
*[[Soft tissue sarcoma]]
 +
**[[Leiomyosarcoma]]
 +
**[[Liposarcoma]]
  
 
==Patient drug information==
 
==Patient drug information==
−
*[http://chemocare.com/chemotherapy/drug-info/dacarbazine.aspx Dacarbazine (DTIC) patient drug information (Chemocare)]<ref>[http://chemocare.com/chemotherapy/drug-info/dacarbazine.aspx Dacarbazine (DTIC) patient drug information (Chemocare)]</ref>
+
*[https://chemocare.com/druginfo/dacarbazine.aspx Dacarbazine (DTIC) patient drug information (Chemocare)]<ref>[https://chemocare.com/druginfo/dacarbazine.aspx Dacarbazine (DTIC) patient drug information (Chemocare)]</ref>
 
*[http://www.uptodate.com/contents/dacarbazine-patient-drug-information Dacarbazine (DTIC) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/dacarbazine-patient-drug-information Dacarbazine (DTIC) patient drug information (UpToDate)]</ref>
 
*[http://www.uptodate.com/contents/dacarbazine-patient-drug-information Dacarbazine (DTIC) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/dacarbazine-patient-drug-information Dacarbazine (DTIC) patient drug information (UpToDate)]</ref>
  
 
==History of changes in FDA indication==
 
==History of changes in FDA indication==
−
* 5/27/1975: Initial FDA approval
+
*1975-05-27: Initial FDA approval
−
 
+
*Uncertain date: indicated in the treatment of metastatic malignant [[melanoma]]. ''(No supporting studies are cited)''
 +
*Uncertain date: Indicated for [[Classical Hodgkin lymphoma|Hodgkin's disease]] as a second-line therapy when used in combination with other effective agents. ''(No supporting studies are cited)''
 +
==History of changes in EMA indication==
 +
*1978-02-01: EURD
 +
==History of changes in PMDA indication==
 +
*2013-03-25: New additional indication and a new dosage for the treatment of [[pheochromocytoma]].
 
==Also known as==
 
==Also known as==
−
DIC, DTIC-Dome, Imidazole carboxamide
+
*'''Generic names:''' dacarbazin, DTIC, imidazole carboxamide
 +
*'''Brand names:''' Bazipar, Cedcozine, Dacarba, Dacarex, Dacin, Dacmed, Darbazine, Dazine, Decarb, Oncodac, Zydac
  
 
==References==
 
==References==
 
<references/>
 
<references/>
  
−
[[Category:Drug index]]
+
[[Category:Drugs]]
−
[[Category:Chemotherapy]]
 
 
[[Category:Intravenous medications]]
 
[[Category:Intravenous medications]]
−
[[Category:Irritant chemotherapy]]
+
[[Category:Irritant]]
  
 
[[Category:Alkylating agents]]
 
[[Category:Alkylating agents]]
−
[[Category:DNA synthesis inhibitors]]
+
[[Category:Triazenes]]
 +
[[Category:Human DNA synthesis inhibitors]]
 
[[Category:Antimetabolites]]
 
[[Category:Antimetabolites]]
−
[[Category:Purine analogues]]
+
[[Category:Purine analogs]]
  
−
[[Category:Hodgkin lymphoma medications]]
+
[[Category:Classical Hodgkin lymphoma medications]]
 
[[Category:Hodgkin lymphoma, nodular lymphocyte-predominant medications]]
 
[[Category:Hodgkin lymphoma, nodular lymphocyte-predominant medications]]
 +
[[Category:Leiomyosarcoma medications]]
 +
[[Category:Liposarcoma medications]]
 
[[Category:Melanoma medications]]
 
[[Category:Melanoma medications]]
−
[[Category:Neuroendocrine tumor medications]]
+
[[Category:Neuroblastoma medications]]
−
[[Category:Sarcoma medications]]
+
[[Category:Pheochromocytoma medications]]
 +
[[Category:Soft tissue sarcoma medications]]
 +
[[Category:Uveal melanoma medications]]
  
−
[[Category:Drugs FDA approved in 1975]]
+
[[Category:FDA approved in 1975]]
 +
[[Category:EMA approved in 1978]]
 
[[Category:WHO Essential Cancer Medicine]]
 
[[Category:WHO Essential Cancer Medicine]]

Latest revision as of 13:27, 23 September 2023

General information

Class/mechanism: Alkylator, purine analog, inhibits DNA synthesis; exact mechanism unclear. Converted to the active alkylating metabolite MTIC.[1][2]
Route: IV
Extravasation: irritant

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]

Diseases for which it is established (work in progress)

Diseases for which it is used

Patient drug information

History of changes in FDA indication

  • 1975-05-27: Initial FDA approval
  • Uncertain date: indicated in the treatment of metastatic malignant melanoma. (No supporting studies are cited)
  • Uncertain date: Indicated for Hodgkin's disease as a second-line therapy when used in combination with other effective agents. (No supporting studies are cited)

History of changes in EMA indication

  • 1978-02-01: EURD

History of changes in PMDA indication

  • 2013-03-25: New additional indication and a new dosage for the treatment of pheochromocytoma.

Also known as

  • Generic names: dacarbazin, DTIC, imidazole carboxamide
  • Brand names: Bazipar, Cedcozine, Dacarba, Dacarex, Dacin, Dacmed, Darbazine, Dazine, Decarb, Oncodac, Zydac

References

  1. ↑ 1.0 1.1 Dacarbazine (DTIC) package insert
  2. ↑ Dacarbazine (DTIC) package insert (locally hosted backup)
  3. ↑ Dacarbazine (DTIC) patient drug information (Chemocare)
  4. ↑ Dacarbazine (DTIC) patient drug information (UpToDate)
Retrieved from "https://hemonc.org/w/index.php?title=Dacarbazine_(DTIC)&oldid=78140"